(NewsDirect)
Mindset Pharma CEO James Lanthier andPharmAla CEO Nick Kadysh join Proactive's Natalie Stoberman toannounce their first sale of pharmaceutical grade psilocybin into theAustralian market.
Lanthier andKadysh said the psilocybin is being purchased by Reset Mind SciencesLimited, a Western Australian based company focused on psychedelicmedicines, and a subsidiary of ASX-listed Little GreenPharma.
The CEOs added that regulatory developments in Australiahave opened the door to more opportunities for their partnership thatcombines Mindset's novel synthesis processes and PharmAla'ssales infrastructure.
ContactDetails
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.